Canada markets open in 8 hours 11 minutes

Akero Therapeutics, Inc. (0K4.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
20.31-0.48 (-2.31%)
At close: 08:00AM CEST
Full screen
Previous Close20.79
Open20.31
Bid20.41 x N/A
Ask20.52 x N/A
Day's Range20.31 - 20.31
52 Week Range10.80 - 55.00
Volume10
Avg. Volume18
Market Cap1.4B
Beta (5Y Monthly)-0.38
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

    SOUTH SAN FRANCISCO, Calif., March 08, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, announced today the closing of its previously announced underwritten public offering of 12,650,000 shares of its common stock at a public offering price of $29.00 per share, which includes the exercise in full by the underwriters of their option to pur

  • GlobeNewswire

    Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology

    As reported previously, the addition of EFX to GLP-1 receptor agonist therapy had a safety and tolerability profile comparable to that of EFX alone and led to statistically significant improvements in non-invasive markers of liver injury and fibrosis and of metabolic health Results indicate potential of EFX to improve resolution of steatohepatitis and fibrosis for patients with MASH and type 2 diabetes already taking a GLP-1 receptor agonist SOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEW

  • GlobeNewswire

    Akero Therapeutics Announces Pricing of Public Offering of Common Stock

    SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, announced today the pricing of an underwritten public offering of 11,000,000 shares of its common stock at a public offering price of $29.00 per share. All of the shares in the offering are being offered by Akero Therapeutics. In addition, Akero Therap